Molecular subtypes and outcomes in regorafenib-treated patients with metastatic colorectal cancer (mCRC) enrolled in the CORRECT trial.

• Teufel, Michael Bayer Pharma AG, Berlin, Germany
• Schwenke, Susanne Bayer Pharma AG, Berlin, Germany
• Seidel, Henrik Bayer Pharma AG, Berlin, Germany
• Beckmann, Georg Bayer Pharma AG, Berlin, Germany
• Reischl, Joachim Bayer Pharma AG, Berlin, Germany
• Vonk, Richardus Bayer Pharma AG, Berlin, Germany
• Lenz, Heinz-Josef VSC/Norris Comprehensive Cancer Centre, Los Angeles, CA
• Tabernero, Josep Vall d’Hebron University Hospital, Barcelona, Spain
• Siena, Salvatore Niguarda Cancer Center, Ospedale Niguarda Ca’ Granda, Milan, Italy
• Grothey, Axel Mayo Clinic, Rochester, MN
• Van Cutsem, Eric University Hospitals Gasthuisberg, Leuven, Belgium
• Jeffers, Michael Bayer HealthCare Pharmaceuticals, Whippany, NJ
• Wilhelm, Scott Bayer HealthCare Pharmaceuticals, Montville, NJ
• Wagner, Andrea Bayer HealthCare Pharmaceuticals, Berlin, Germany
• Laurent, Dirk Bayer Healthcare Pharmaceuticals AG, Berlin, Germany
• Kobina, Svetlana Bayer Healthcare, Pharmaceuticals, Whippany, NJ
• Rutstein, Mark Daniel Bayer HealthCare, Whippany, NJ
• Wirapati, Pratyaksha Swiss Institute of Bioinformatics, Lausanne, Switzerland
• Guinney, Justin Sage Bionetworks, Seattle, WA
• Tejpar, Sabine University of Leuven, KUL, Leuven, Belgium

Cancer Research

Oncology